Rigrodsky & Long, P.A. Announces Investigation Of Onyx Pharmaceuticals, Inc. Buyout

Rigrodsky & Long, P.A.:
  • Do you own shares of Onyx Pharmaceuticals, Inc. (NASDAQ GS: ONXX )?
  • Did you purchase any of your shares prior to August 25, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”) (NASDAQ GS: ONXX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Amgen Inc. (“Amgen”) (NASDAQ GS: AMGN) in a transaction valued at approximately $10.4 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Under the terms of the agreement, public shareholders of Onyx will receive $125.00 per share in cash for each share of Onyx they own.

The investigation concerns whether Onyx’s board of directors failed to adequately shop the Company and obtain the best possible value for Onyx’s shareholders before entering into an agreement with Amgen. According to Yahoo! Finance, at least one analyst has set a price target for Onyx stock at $160.00 per share.

If you own the common stock of Onyx and purchased your shares before August 25, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brian Long or Shaye Fuchs at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

If you liked this article you might like

Biotech Stock Mailbag: Rebounding From Hillary's Drug Tweet; Global Blood Weighs on Bluebird

The Street Can't Help but Love Amgen

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Trade-Ideas: Onyx Pharmaceuticals (ONXX) Is Today's "Water-Logged And Getting Wetter" Stock

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan